RGRX RegeneRX Biopharmaceuticals Inc (CE)

August 2, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Ladies and Gentlemen:

We are filing this letter in order to provide the staff of the Division of Corporation Finance sufficient time to perform its customary screening and review of registration statements prior to their effectiveness.

Pursuant to Rule 473(c) of the Securities Act of 1933, as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the cover page of Amendment No. 1 to the Registration Statement on Form S-1, File No. 333-212606, filed by RegeneRx Biopharmaceuticals, Inc. on July 29, 2016:

“The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a) of the Securities Act of 1933, as amended, may determine.”

If you have any questions or comments in connection with this delaying amendment, please contact Andrew M. Nick (612-492-7457) or Todd A. Taylor (612-492-7355) of Fredrikson & Byron, P.A.

Grafico Azioni RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
Storico
Da Giu 2023 a Giu 2024